BSSE spinoff Engimmune raises seed financing to develop novel T-cell receptor therapeutics

Exciting news from our youngest spinoff company: Engimmune Therapeutics completed a CHF 15.5 million seed financing round to boost R&D of novel T-cell receptor (TCR)-based therapeutics. Proceeds from the financing will be used to further build Engimmune’s pipeline, expand the research team in Switzerland and build a foothold in Denmark, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.

Engimmune is a platform company using cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment. By combining genome editing, functional screening, deep sequencing and machine learning, Engimmune addresses major efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapies. Engimmune's lead products are focused on oncology, with potential to expand to autoimmune diseases in the future.

I am thrilled that a company based on the systems, synthetic and computational biology methods that are the foundation for D-BSSE, and focused specifically on cancer immunotherapy has received this financing. We hope to someday soon make a real translational impact for the benefit of patients.Sai Reddy, co-founder of Engimmune Therapeutics and professor of systems and synthetic immunology at D-BSSE

The company originates from the Synthetic Immunology lab led by Sai Reddy and was initially incubated through BaseLaunch; the seed round is funded by Pureos Bioventures and Novo Holdings.